Literature DB >> 26043762

Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

S M Brankley1, K C Halling1, S M Jenkins2, M R Timmer3, P G Iyer3, T C Smyrk1, E G Barr Fritcher1, J S Voss1, B R Kipp1, M B Campion1, L S Lutzke3, D M Minot1, K K Wang3.   

Abstract

Barrett's esophagus (BE) with high-grade dysplasia (HGD) defines a group of individuals at high risk of progression to esophageal adenocarcinoma (EA). Fluorescence in situ hybridization (FISH) has been shown to be useful for the detection of dysplasia and EA in endoscopic brushing specimens from BE patients. The aim of this study was to determine whether FISH in combination with histological findings would further identify more rapid progressors to EA. This is a retrospective cohort study of high-risk patients, having a history of biopsy-confirmed HGD without EA, with an endoscopic brushing specimen analyzed by FISH while undergoing endoscopic surveillance and treatment between April 2003 and October 2010. Brushing specimens were assessed by FISH probes targeting 8q24 (MYC), 9p21 (CDKN2A), 17q12 (ERBB2), and 20q13 (ZNF217) and evaluated for the presence of polysomy, defined as multiple chromosomal gains (displaying ≥ 3 signals for ≥ 2 probes). Specimens containing ≥ 4 cells exhibiting polysomy were considered polysomic. HGD was confirmed by at least two experienced gastrointestinal pathologists. Of 245 patients in this study, 93 (38.0%) had a polysomic FISH result and 152 (62.0%) had a non-polysomic FISH result. Median follow-up was 3.6 years (interquartile range [IQR] 2-5 years). Patients with a polysomic FISH result had a significantly higher risk of developing EA within 2 years (14.2%) compared with patients with a non-polysomic FISH result (1.4%, P < 0.001). These findings suggest that a polysomic FISH result in BE patients with simultaneous HGD identifies patients at a higher risk for developing EA compared with those with non-polysomy.
© 2015 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  Barrett's esophagus; FISH; cytology; esophageal adenocarcinoma; polysomy

Mesh:

Substances:

Year:  2015        PMID: 26043762      PMCID: PMC5563668          DOI: 10.1111/dote.12372

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  12 in total

1.  Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.

Authors:  Elizabeth L Bird-Lieberman; Jason M Dunn; Helen G Coleman; Pierre Lao-Sirieix; Dahmane Oukrif; Christina E Moore; Sibu Varghese; Brian T Johnston; Kenneth Arthur; Damian T McManus; Marco R Novelli; Maria O'Donovan; Christopher R Cardwell; Laurence B Lovat; Liam J Murray; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2012-07-03       Impact factor: 22.682

2.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

3.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Authors:  Kenneth K Wang; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

4.  Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

Authors:  Amy E Noffsinger
Journal:  Gastrointest Cancer Res       Date:  2008-11

5.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

6.  The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.

Authors:  Shannon M Brankley; Kenneth K Wang; Aaron R Harwood; Dylan V Miller; Mona S Legator; Lori S Lutzke; Benjamin R Kipp; Larry E Morrison; Kevin C Halling
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

7.  Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years.

Authors:  M Hage; P D Siersema; H van Dekken; E W Steyerberg; J Dees; E J Kuipers
Journal:  Scand J Gastroenterol       Date:  2004-12       Impact factor: 2.423

8.  A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.

Authors:  Emily G Barr Fritcher; Shannon M Brankley; Benjamin R Kipp; Jesse S Voss; Michael B Campion; Larry E Morrison; Mona S Legator; Lori S Lutzke; Kenneth K Wang; Thomas J Sebo; Kevin C Halling
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

9.  Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.

Authors:  K Nadine Phoa; Frederike G I van Vilsteren; Bas L A M Weusten; Raf Bisschops; Erik J Schoon; Krish Ragunath; Grant Fullarton; Massimiliano Di Pietro; Narayanasamy Ravi; Mike Visser; G Johan Offerhaus; Cees A Seldenrijk; Sybren L Meijer; Fiebo J W ten Kate; Jan G P Tijssen; Jacques J G H M Bergman
Journal:  JAMA       Date:  2014-03-26       Impact factor: 56.272

10.  NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Authors:  Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  4 in total

1.  A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.

Authors:  John M Poneros; Adam S Faye; Emily G Barr Fritcher; Ananda Sen; Sharmila Anandasabapathy; Robert S Bresalier; Norman Marcon; D Kim Turgeon; Henry Appelman; Daniel Normolle; Larry E Morrison; Dean E Brenner; Kevin C Halling
Journal:  Dig Dis Sci       Date:  2017-03-06       Impact factor: 3.199

2.  Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.

Authors:  Christopher Douville; Helen R Moinova; Prashanthi N Thota; Nicholas J Shaheen; Prasad G Iyer; Marcia Irene Canto; Jean S Wang; John A Dumot; Ashley Faulx; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Sanford D Markowitz; Chetan Bettegowda; Joseph E Willis; Amitabh Chak
Journal:  Gastroenterology       Date:  2021-01-22       Impact factor: 22.682

Review 3.  Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.

Authors:  Won-Tak Choi; Gregory Y Lauwers; Elizabeth A Montgomery
Journal:  Mod Pathol       Date:  2022-03-08       Impact factor: 8.209

4.  Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers.

Authors:  William M Grady; Ming Yu; Sanford D Markowitz; Amitabh Chak
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-22       Impact factor: 4.254

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.